Loading...

Polmed

WSE:POM
Snowflake Description

Flawless balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
POM
WSE
PLN47M
Market Cap
  1. Home
  2. PL
  3. Healthcare
Company description

Polmed S.A. provides medical services to private and institutional clients. The last earnings update was 89 days ago. More info.


Add to Portfolio Compare Print
POM Share Price and Events
7 Day Returns
0%
WSE:POM
0.6%
PL Healthcare
1%
PL Market
1 Year Returns
16.5%
WSE:POM
-3.1%
PL Healthcare
-9.3%
PL Market
POM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Polmed (POM) 0% 0% -0.7% 16.5% 1.4% 11.5%
PL Healthcare 0.6% 1.8% -10.6% -3.1% -17.1% -5.2%
PL Market 1% 5% -5.5% -9.3% 40.1% 35.2%
1 Year Return vs Industry and Market
  • POM outperformed the Healthcare industry which returned -3.1% over the past year.
  • POM outperformed the Market in Poland which returned -9.3% over the past year.
Price Volatility
POM
Industry
5yr Volatility vs Market

Value

 Is Polmed undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Polmed. This is due to cash flow or dividend data being unavailable. The share price is PLN2.9.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Polmed's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Polmed's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
WSE:POM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in PLN PLN0.31
WSE:POM Share Price ** WSE (2018-09-21) in PLN PLN2.9
Poland Healthcare Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Companies 9.95x
Poland Market PE Ratio Median Figure of 442 Publicly-Listed Companies 10.15x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Polmed.

WSE:POM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= WSE:POM Share Price ÷ EPS (both in PLN)

= 2.9 ÷ 0.31

9.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Polmed is good value based on earnings compared to the PL Healthcare industry average.
  • Polmed is good value based on earnings compared to the Poland market.
Price based on expected Growth
Does Polmed's expected growth come at a high price?
Raw Data
WSE:POM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 9.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
5.6%per year
Europe Healthcare Industry PEG Ratio Median Figure of 35 Publicly-Listed Healthcare Companies 1.26x
Poland Market PEG Ratio Median Figure of 102 Publicly-Listed Companies 0.98x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Polmed, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Polmed's assets?
Raw Data
WSE:POM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in PLN PLN1.70
WSE:POM Share Price * WSE (2018-09-21) in PLN PLN2.9
Poland Healthcare Industry PB Ratio Median Figure of 11 Publicly-Listed Healthcare Companies 1.71x
Poland Market PB Ratio Median Figure of 673 Publicly-Listed Companies 0.95x
WSE:POM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= WSE:POM Share Price ÷ Book Value per Share (both in PLN)

= 2.9 ÷ 1.70

1.71x

* Primary Listing of Polmed.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Polmed is good value based on assets compared to the PL Healthcare industry average.
X
Value checks
We assess Polmed's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Polmed has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Polmed expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Polmed, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
5.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Polmed expected to grow at an attractive rate?
  • Polmed's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
  • Polmed's earnings growth is positive but not above the Poland market average.
  • Unable to compare Polmed's revenue growth to the Poland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
WSE:POM Future Growth Rates Data Sources
Data Point Source Value (per year)
WSE:POM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 5.6%
Poland Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Europe Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 7.5%
Poland Market Earnings Growth Rate Market Cap Weighted Average 9.1%
Poland Market Revenue Growth Rate Market Cap Weighted Average 6.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
WSE:POM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in PLN Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
WSE:POM Future Estimates Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
WSE:POM Past Financials Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income *
2018-06-30 119 2 9
2018-03-31 114 12 7
2017-12-31 110 8 6
2017-09-30 106 6 4
2017-06-30 100 7 4
2017-03-31 98 5 5
2016-12-31 92 6 4
2016-09-30 88 7 6
2016-06-30 84 7 5
2016-03-31 78 9 5
2015-12-31 73 9 5
2015-09-30 69 8 4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Polmed's earnings are expected to grow by 5.6% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Polmed is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
WSE:POM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Polmed Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:POM Future Estimates Data
Date (Data in PLN Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
WSE:POM Past Financials Data
Date (Data in PLN Millions) EPS *
2018-06-30 0.31
2018-03-31 0.26
2017-12-31 0.21
2017-09-30 0.15
2017-06-30 0.14
2017-03-31 0.16
2016-12-31 0.15
2016-09-30 0.20
2016-06-30 0.18
2016-03-31 0.17
2015-12-31 0.18
2015-09-30 0.13

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Polmed will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Polmed's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Poland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Polmed has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Polmed performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Polmed's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Polmed has delivered over 20% year on year earnings growth in the past 5 years.
  • Polmed's 1-year earnings growth exceeds its 5-year average (125.7% vs 27.7%)
  • Polmed's earnings growth has exceeded the PL Healthcare industry average in the past year (125.7% vs 81.4%).
Earnings and Revenue History
Polmed's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Polmed Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:POM Past Revenue, Cash Flow and Net Income Data
Date (Data in PLN Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 118.77 8.97 4.58
2018-03-31 113.92 7.41 4.46
2017-12-31 109.83 5.98 4.23
2017-09-30 105.65 4.21 4.54
2017-06-30 99.99 3.98 4.82
2017-03-31 97.50 4.55 4.82
2016-12-31 92.05 4.33 4.84
2016-09-30 87.81 5.63 4.38
2016-06-30 84.30 5.05 3.96
2016-03-31 77.64 4.88 3.69
2015-12-31 72.86 5.22 3.53
2015-09-30 68.79 3.77 3.39
2015-06-30 65.56 3.70 3.27
2015-03-31 63.35 3.25 3.34
2014-12-31 61.08 2.33 3.41
2014-09-30 59.07 3.86 3.56
2014-06-30 57.26 3.71 3.54
2014-03-31 56.01 3.34 3.16
2013-12-31 54.66 2.90 3.46
2013-09-30 52.62 0.10 4.03
2013-06-30 50.82 -1.44 4.91
2013-03-31 48.61 -2.68 5.66
2012-12-31 45.49 -3.37 5.06
2012-09-30 41.81 -6.58 5.32
2012-06-30 38.10 -6.09 4.20
2012-03-31 35.40 -5.22 3.62
2011-12-31 32.11 -3.60 3.64

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Polmed has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Polmed used its assets more efficiently than the PL Healthcare industry average last year based on Return on Assets.
  • Polmed has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Polmed's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Polmed has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Polmed's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Polmed's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Polmed is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Polmed's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Polmed's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 7.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Polmed Company Filings, last reported 4 months ago.

WSE:POM Past Debt and Equity Data
Date (Data in PLN Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 48.62 3.54 2.90
2018-03-31 46.02 4.88 11.72
2017-12-31 43.29 5.15 7.73
2017-09-30 41.43 5.23 4.61
2017-06-30 39.53 5.71 4.10
2017-03-31 42.00 4.71 4.70
2016-12-31 40.70 6.15 5.40
2016-09-30 40.48 5.44 3.65
2016-06-30 38.75 7.67 3.83
2016-03-31 41.12 6.06 6.06
2015-12-31 40.04 8.25 6.37
2015-09-30 38.61 6.51 2.61
2015-06-30 37.41 6.24 4.03
2015-03-31 36.34 7.14 0.88
2014-12-31 36.34 7.14 0.88
2014-09-30 36.42 8.74 0.47
2014-06-30 35.34 9.35 0.28
2014-03-31 35.58 10.54 0.58
2013-12-31 35.07 11.36 0.46
2013-09-30 33.61 12.45 0.26
2013-06-30 32.68 12.27 0.19
2013-03-31 31.62 7.96 0.36
2012-12-31 32.17 14.03 0.25
2012-09-30 34.24 8.41 0.28
2012-06-30 34.89 13.89 0.72
2012-03-31 43.39 9.27 1.51
2011-12-31 36.05 14.22 3.91
  • Polmed's level of debt (7.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (37.5% vs 7.3% today).
  • Debt is well covered by operating cash flow (62.2%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 198.4x coverage).
X
Financial health checks
We assess Polmed's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Polmed has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Polmed's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Polmed dividends.
If you bought PLN2,000 of Polmed shares you are expected to receive PLN0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Polmed's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Polmed's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
WSE:POM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 45 Stocks 1.5%
Poland Market Average Dividend Yield Market Cap Weighted Average of 210 Stocks 3.5%
Poland Minimum Threshold Dividend Yield 10th Percentile 1.4%
Poland Bottom 25% Dividend Yield 25th Percentile 2.8%
Poland Top 25% Dividend Yield 75th Percentile 7.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

WSE:POM Future Dividends Estimate Data
Date (Data in PLN) Dividend per Share (annual) Avg. No. Analysts
WSE:POM Past Annualized Dividends Data
Date (Data in PLN) Dividend per share (annual) Avg. Yield (%)
2018-08-30 0.000 0.000
2018-05-25 0.000 0.000
2017-09-15 0.120 4.738
2017-03-23 0.120 4.669
2016-05-16 0.140 4.867
2016-03-21 0.140 4.776
2015-11-02 0.060 2.132
2015-03-19 0.060 2.172
2014-11-14 0.040 1.894
2014-08-28 0.040 1.815
2014-05-14 0.040 1.783
2014-03-21 0.040 1.507
2014-01-15 0.040 1.426
2012-05-15 0.030 1.659
2011-09-05 0.040 2.066
2011-03-23 0.040 1.535
2010-12-23 0.040 1.399

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Polmed has not reported any payouts.
  • Unable to verify if Polmed's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Polmed's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Polmed has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Polmed's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Polmed afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Polmed has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Polmed's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Radoslaw Szubert
COMPENSATION PLN479,000
CEO Bio

Mr. Radosaw Szubert serves as the Chairman of the Board at Polmed S.A.

CEO Compensation
  • Radoslaw's compensation has been consistent with company performance over the past year.
  • Radoslaw's remuneration is higher than average for companies of similar size in Poland.
Management Team

Radoslaw Szubert

TITLE
Chairman of the Board
COMPENSATION
PLN479K

Romuald Magdon

TITLE
Vice President of the Board of Directors
COMPENSATION
PLN479K

Alicja Czechowska

TITLE
Financial Director

Dorota Cerowska

TITLE
Chief Accountant

Katarzyna Plit-Muszynska

TITLE
Sales Director

Grazyna Fijal

TITLE
Staff Director

Grazyna Jendyk

TITLE
Manager of the Board of Directors Office
Board of Directors

Krzysztof Plachta

TITLE
Chairperson of the Supervisory Board
COMPENSATION
PLN5K
AGE
59

Robert Bozyk

TITLE
Vice Chairperson of the Supervisory Board

Monika Gaszewska

TITLE
Vice President of the Supervisory Board
COMPENSATION
PLN4K

Tomasz Polakowski

TITLE
Member of Supervisory Board
COMPENSATION
PLN3K

Boleslaw Rutkowski

TITLE
Member of the Supervisory Board

Jacek Dudkiewicz

TITLE
Member of Supervisory Board
COMPENSATION
PLN4K
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (PLN) Value (PLN)
X
Management checks
We assess Polmed's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Polmed has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

What Investors Should Know About Polmed SA's (WSE:POM) Financial Strength

Polmed SA (WSE:POM) is a small-cap stock with a market capitalization of zł83.5m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

What Does Polmed SA's (WSE:POM) PE Ratio Tell You?

This analysis is intended to introduce important early concepts to people who are starting to invest. … and want to start learning about core concepts of fundamental analysis on practical examples from today's market. … While this makes POM appear like a great stock to buy, you might change your mind after I explain the assumptions behind the P/E ratio.

Simply Wall St -

Want To Invest In Polmed SA (WSE:POM)? Here's How It Performed Lately

Measuring Polmed SA's (WSE:POM) track record of past performance is a useful exercise for investors. … Today I will assess POM's recent performance announced on 31 December 2017 and weigh these figures against its long-term trend and industry movements. … How Did POM's Recent Performance Stack Up Against Its Past.

Simply Wall St -

Polmed SA (WSE:POM): A Fundamentally Attractive Investment

Building up an investment case requires looking at a stock holistically. … Today I've chosen to put the spotlight on Polmed SA (WSE:POM) due to its excellent fundamentals in more than one area.

Simply Wall St -

Breaking Down Polmed SA.'s (WSE:POM) Ownership Structure

I am going to take a deep dive into Polmed SA.’s (WSE:POM) most recent ownership structure, not a frequent subject of discussion among individual investors. … See our latest analysis for Polmed WSE:POM Ownership_summary Jun 4th 18 Institutional Ownership Due to the big order sizes of institutional investors, a company's shares can experience large, one-sided momentum, driven by high volume of shares removed from, or injected into, the market. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: With a low level of institutional ownership, investors in POM need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.

Simply Wall St -

Is Polmed SA. (WSE:POM) A Buy At Its Current PE Ratio?

By comparing a stock’s price per share to its earnings per share, we are able to see how much investors are paying for each dollar of the company’s earnings. … Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for POM Price per share = PLN2.78 Earnings per share = PLN0.209 ∴ Price-Earnings Ratio = PLN2.78 ÷ PLN0.209 = 13.3x On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. … For example, if you inadvertently compared lower risk firms with POM, then investors would naturally value POM at a lower price since it is a riskier investment.

Simply Wall St -

Polmed SA. (WSE:POM) Delivered A Better ROE Than The Industry, Here’s Why

Check out our latest analysis for Polmed Peeling the layers of ROE – trisecting a company’s profitability Return on Equity (ROE) is a measure of Polmed’s profit relative to its shareholders’ equity. … This is called the Dupont Formula: Dupont Formula ROE = profit margin × asset turnover × financial leverage ROE = (annual net profit ÷ sales) × (sales ÷ assets) × (assets ÷ shareholders’ equity) ROE = annual net profit ÷ shareholders’ equity WSE:POM Last Perf Apr 24th 18 Basically, profit margin measures how much of revenue trickles down into earnings which illustrates how efficient the business is with its cost management. … Polmed exhibits a strong ROE against its peers, as well as sufficient returns to cover its cost of equity.

Simply Wall St -

With A -25.19% Earnings Drop, Did Polmed SA. (WSE:POM) Really Underperform?

View our latest analysis for Polmed Was POM's recent earnings decline worse than the long-term trend and the industry? … I prefer to use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … For Polmed, its most recent trailing-twelve-month earnings is ZŁ4.21M, which compared to the prior year's figure, has dropped by -25.19%.

Simply Wall St -

Polmed SA. (WSE:POM): Time For A Financial Health Check

With this reduction in debt, POM's cash and short-term investments stands at ZŁ5.40M for investing into the business. … Additionally, POM has generated cash from operations of ZŁ5.80M in the last twelve months, resulting in an operating cash to total debt ratio of 94.29%, indicating that POM’s operating cash is sufficient to cover its debt. … For POM, the ratio of 53.62x suggests that interest is comfortably covered, which means that debtors may be willing to loan the company more money, giving POM ample headroom to grow its debt facilities.Next Steps: POM’s high cash coverage and low debt levels indicate its ability to utilise its borrowings efficiently in order to generate ample cash flow.

Simply Wall St -

Company Info

Map
Description

Polmed S.A. provides medical services to private and institutional clients. The company offers services, including basic and specialist medical care, full medical diagnostics, rehabilitation, dentistry, aesthetic medicine, and home visit. It operates a network of own and partner medical facilities. The company was founded in 1999 and is based in Starogard Gdanski, Poland. Polmed S.A. is a subsidiary of Polmed Medical Limited.

Details
Name: Polmed S.A.
POM
Exchange: WSE
Founded: 1999
PLN46,654,359
16,087,710
Website: http://www.polmed.pl
Address: Polmed S.A.
Os.Kopernika 21,
Starogard Gdanski,
83-200,
Poland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
WSE POM Common Bearer Shares Warsaw Stock Exchange PL PLN 23. Dec 2010
LSE 0Q3O Common Bearer Shares London Stock Exchange GB PLN 23. Dec 2010
Number of employees
Current staff
Staff numbers
0
Polmed employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/11/27 19:06
End of day share price update: 2018/09/21 00:00
Last estimates confirmation: 2016/03/21
Last earnings filing: 2018/08/30
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.